Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18258254 | 1.00 | MAPT (0.35) | MAPTLMNASMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL19171687 | 1.00 | MAPT (0.35) | MAPTLMNASMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL19171690 | 1.00 | MAPT (0.35) | MAPTLMNASMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL18857002 | 0.82 | KDM4E (0.34) | MAPTLMNASMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL18257784 | 0.80 | KDM4E (0.33) | MAPTLMNASMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL19164687 | 0.80 | KDM4E (0.33) | MAPTLMNASMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL19164693 | 0.80 | KDM4E (0.33) | MAPTLMNASMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL18258266 | 0.79 | ALDH1A1 (0.47) | MAPTLMNASMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL12597187 | 0.79 | ALDH1A1 (0.47) | MAPTLMNASMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL20644697 | 0.78 | KDM4E (0.30) | MAPTLMNASMN1; SMN2KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9839636-B2 | Itraconazole analogues and methods of use thereof | UNIVERSITY OF CONNECTICUT (US) | 2017-12-12 | — | — | US | disclosed |
| US-20170209436-A1 | ITRACONAZOLE ANALOGUES AND METHODS OF USE THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-07-27 | — | — | US | disclosed |
| US-9650365-B2 | Itraconazole analogues and methods of use thereof | UNIVERSITY OF CONNECTICUT (US) | 2017-05-16 | — | — | US | disclosed |
| US-20160340346-A1 | ITRACONAZOLE ANALOGUES AND METHODS OF USE THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160340346-A1 | ITRACONAZOLE ANALOGUES AND METHODS OF USE THEREOF | GLI1, SHH, SMO | MAPT 4271/4885LMNA 4777/4885SMN1; SMN2 4459/4885 |
| US-20170209436-A1 | ITRACONAZOLE ANALOGUES AND METHODS OF USE THEREOF | GLI1, SHH, SMO | MAPT 4271/4885LMNA 4777/4885SMN1; SMN2 4459/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.